Isoleucine
| 證據等級: L5 | 預測適應症: 1 個 |
目錄
Isoleucine: From No Approved Indication to Gastroparesis
One-Sentence Summary
Isoleucine is an essential branched-chain amino acid (BCAA) with no approved therapeutic indication and no TFDA market registration in Taiwan. The TxGNN model predicts it may be effective for Gastroparesis, with a prediction score of 99.32%, but currently zero clinical trials and zero publications support this direction — the signal comes from knowledge-graph embedding similarity alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | None approved — essential amino acid, nutritional/metabolic use only; no TFDA license on record |
| Predicted New Indication | Gastroparesis |
| TxGNN Prediction Score | 99.32% |
| Evidence Level | L5 (model prediction only, no clinical or literature support) |
| Taiwan Market Status | Not Marketed (未上市) |
| Number of TFDA Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available for isoleucine as a therapeutic agent. Isoleucine is one of three branched-chain amino acids (with leucine and valine), primarily studied for roles in protein synthesis and muscle/energy metabolism. It has no established pharmacological indication and no marketing license in Taiwan, so there is no “original indication” from which to draw a mechanistic bridge to gastroparesis.
The TxGNN score of 99.32% reflects similarity in the model’s learned knowledge-graph embedding space, not a validated biological or clinical link. There is no published evidence — preclinical, observational, or clinical — establishing a causal pathway between BCAA supplementation and gastric motility or gastric emptying. Without a mechanistic anchor (original indication, known MOA, or supporting trials/literature), this prediction should be treated as a hypothesis-generating signal only, not as evidence of therapeutic plausibility.
Given the absence of any corroborating clinical or mechanistic data, this candidate currently rests entirely on computational prediction and requires substantial additional evidence before any further evaluation is warranted.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Taiwan Market Information (TFDA)
Isoleucine is not marketed in Taiwan and has no TFDA registration records on file (0 licenses). No product, dosage form, or approved indication text is available for this candidate.
Safety Considerations
Please refer to the TFDA-approved Package Insert (PI) for safety information. Report suspected adverse drug reactions to the Taiwan FDA (TFDA).
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by a knowledge-graph similarity score (L5), with no clinical trials, no literature, no known MOA, and no market presence in Taiwan to anchor a mechanistic rationale. There is currently no basis to advance this candidate beyond initial screening.
To proceed, the following is needed:
- TFDA package insert / warnings and contraindications data (currently blocking — DG001)
- Mechanism of action data for isoleucine as a pharmacological agent (DG002)
- Preclinical or mechanistic studies linking BCAA metabolism to gastric motility/emptying
- Any observational or case-level clinical evidence in gastroparesis populations
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.